WASHINGTON, D.C.—On August 2, 2012, Rep. Ron Paul (R-TX14) introduced the “Compassionate Freedom of Choice Act,” H.R. 6342, a Bill designed to “allow the importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document.” Rep. Paul Broun (R-GA10) and Rep. Richard Hanna (R-NY24) […]
In a 5 to 4 decision the Supreme Court upheld the Federal Patient Protection and Affordable Care Act (PPACA), known to many as “Obamacare.” Somewhat surprising was the Court’s rationale. Leading up to this decision many experts thought Chief Justice Roberts might uphold the law in an effort to overcome public concern for judicial activism. And when […]
On Tuesday, August 2, 2011, Emord & Associates filed comments with the FDA and Office of Management and Budget (OMB) concerning the FDA’s proposed collection of information through 75-day New Dietary Ingredient notifications. We previously reported on the FDA’s proposed New Dietary Ingredient (NDI) guidance here and here. Federal agencies frequently collect information from private […]
Whether evaluating a concept, performing regulatory due diligence, maintaining or prosecuting regulatory filings, or contesting adverse litigation, Emord & Associates provides exceptional counsel for all your litigation and regulatory needs.
11808 Wolf Run Lane
Clifton, VA 20124
Telephone: (202) 466-6937
Telecopier: (202) 466-6938
